Becton, Dickinson and Company (NYSE:BDX) Price Target Raised to $189.00

Posted by John Perry on Feb 14th, 2026

Becton, Dickinson and Company (NYSE:BDX – Free Report) had its price objective increased by TD Cowen from $183.00 to $189.00 in a research report sent to investors on Wednesday,MarketScreener reports. TD Cowen currently has a hold rating on the medical instruments supplier’s stock.

Several other analysts also recently commented on BDX. Wall Street Zen downgraded shares of Becton, Dickinson and Company from a “buy” rating to a “hold” rating in a research report on Saturday, November 8th. Stifel Nicolaus raised their price target on shares of Becton, Dickinson and Company from $210.00 to $215.00 and gave the stock a “buy” rating in a report on Wednesday, January 7th. Wells Fargo & Company dropped their price objective on shares of Becton, Dickinson and Company from $184.00 to $157.00 and set an “equal weight” rating on the stock in a report on Tuesday. Morgan Stanley raised their target price on Becton, Dickinson and Company from $197.00 to $210.00 and gave the company an “overweight” rating in a research note on Tuesday, December 2nd. Finally, Barclays initiated coverage on Becton, Dickinson and Company in a research report on Tuesday. They issued an “overweight” rating and a $202.00 target price for the company. Five research analysts have rated the stock with a Buy rating, ten have issued a Hold rating and one has assigned a Sell rating to the company. Based on data from MarketBeat, the company currently has an average rating of “Hold” and a consensus price target of $195.46.

View Our Latest Report on BDX

Becton, Dickinson and Company Stock Performance

Shares of BDX opened at $175.95 on Wednesday. The company has a current ratio of 1.05, a quick ratio of 0.64 and a debt-to-equity ratio of 0.67. The firm’s fifty day simple moving average is $198.82 and its two-hundred day simple moving average is $192.20. Becton, Dickinson and Company has a 12 month low of $127.59 and a 12 month high of $185.02. The stock has a market capitalization of $50.10 billion, a P/E ratio of 28.70, a price-to-earnings-growth ratio of 2.32 and a beta of 0.25.

Becton, Dickinson and Company (NYSE:BDX – Get Free Report) last announced its quarterly earnings data on Monday, February 9th. The medical instruments supplier reported $2.91 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $2.81 by $0.10. Becton, Dickinson and Company had a return on equity of 15.76% and a net margin of 8.01%.The company had revenue of $5.25 billion for the quarter, compared to the consensus estimate of $5.15 billion. During the same period in the previous year, the business earned $3.43 EPS. The firm’s revenue was up 1.6% compared to the same quarter last year. Becton, Dickinson and Company has set its FY 2026 guidance at 12.350-12.650 EPS. As a group, analysts predict that Becton, Dickinson and Company will post 14.43 EPS for the current year.

Becton, Dickinson and Company Announces Dividend

The business also recently declared a quarterly dividend, which will be paid on Tuesday, March 31st. Shareholders of record on Tuesday, March 10th will be paid a dividend of $1.05 per share. The ex-dividend date is Tuesday, March 10th. This represents a $4.20 dividend on an annualized basis and a yield of 2.4%. Becton, Dickinson and Company’s payout ratio is 68.52%.

Becton, Dickinson and Company declared that its board has initiated a share repurchase plan on Tuesday, January 27th that authorizes the company to buyback $10.00 million in shares. This buyback authorization authorizes the medical instruments supplier to buy up to 0% of its stock through open market purchases. Stock buyback plans are generally a sign that the company’s board believes its shares are undervalued.

Insider Buying and Selling

In other news, EVP Michael David Garrison sold 1,610 shares of the stock in a transaction that occurred on Thursday, January 15th. The stock was sold at an average price of $207.46, for a total value of $334,010.60. Following the completion of the sale, the executive vice president directly owned 12,095 shares of the company’s stock, valued at $2,509,228.70. This represents a 11.75% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink. Over the last three months, insiders sold 2,463 shares of company stock worth $501,530. Insiders own 0.40% of the company’s stock.

Institutional Investors Weigh In On Becton, Dickinson and Company

Institutional investors and hedge funds have recently bought and sold shares of the stock. Crux Wealth Advisors grew its stake in shares of Becton, Dickinson and Company by 0.8% in the 4th quarter. Crux Wealth Advisors now owns 6,297 shares of the medical instruments supplier’s stock worth $1,222,000 after acquiring an additional 49 shares in the last quarter. Larson Financial Group LLC boosted its holdings in Becton, Dickinson and Company by 1.7% during the fourth quarter. Larson Financial Group LLC now owns 3,230 shares of the medical instruments supplier’s stock worth $627,000 after purchasing an additional 53 shares during the last quarter. Camelot Portfolios LLC grew its position in Becton, Dickinson and Company by 1.5% in the 4th quarter. Camelot Portfolios LLC now owns 3,545 shares of the medical instruments supplier’s stock worth $688,000 after purchasing an additional 54 shares in the last quarter. McElhenny Sheffield Capital Management LLC grew its position in Becton, Dickinson and Company by 3.6% in the 4th quarter. McElhenny Sheffield Capital Management LLC now owns 1,590 shares of the medical instruments supplier’s stock worth $309,000 after purchasing an additional 55 shares in the last quarter. Finally, Gilbert & Cook Inc. increased its stake in Becton, Dickinson and Company by 2.0% in the 2nd quarter. Gilbert & Cook Inc. now owns 2,844 shares of the medical instruments supplier’s stock valued at $490,000 after buying an additional 56 shares during the last quarter. 86.97% of the stock is owned by hedge funds and other institutional investors.

More Becton, Dickinson and Company News

Here are the key news stories impacting Becton, Dickinson and Company this week:

Positive Sentiment: Citi raised its price target after a life?sciences sale update, signaling potential value support if BDx proceeds with portfolio moves. Citi raises Becton Dickinson PT to $198
Positive Sentiment: Jefferies issued a buy, supporting the view that BDx’s portfolio reshaping and product investments can sustain growth. Becton Dickinson Gets a Buy from Jefferies
Positive Sentiment: TD Cowen nudged its target higher to $189 (hold), reflecting modest upside from current levels and adding another analyst vote of confidence. TD Cowen adjusts Becton Dickinson PT to $189
Neutral Sentiment: Company Q4 review: management says portfolio reshaping and product investments offset tariff headwinds — useful context for earnings quality but not an immediate directional catalyst. BDX Q4 Deep Dive: Portfolio Reshaping and Product Investments Offset Tariff Headwinds
Negative Sentiment: Zacks Research cut BDX from “hold” to “strong sell,” a notable downgrade that likely pressured sentiment and contributed to the share weakness. Zacks Research downgrade
Negative Sentiment: AmericanBankingNews reports Citigroup lowered a prior target (headline shows a cut to $232), adding further mixed signals from the sell?side. Citigroup Lowers Becton Dickinson PT to $232
Negative Sentiment: JPMorgan and Wells Fargo issued pessimistic forecasts in separate notes, increasing analyst pressure and downside risk in the near term. JPMorgan pessimistic forecast Wells Fargo pessimistic forecast
Negative Sentiment: Coverage flow drove a gap?down headline after the analyst activity, reflecting short?term selling pressure from downgrades and mixed guidance expectations. Shares gap down on analyst downgrade

About Becton, Dickinson and Company

(Get Free Report)

Becton, Dickinson and Company (BDX) is a global medical technology company that develops, manufactures and sells a broad range of medical devices, instrument systems and reagents. BD’s products are used by healthcare institutions, clinical laboratories, life science researchers and the pharmaceutical industry to enable safe, effective delivery of care, specimen collection and diagnostic testing. The company’s operations span multiple business areas focused on medical devices, life sciences research tools and interventional technologies.

BD’s product portfolio includes single-use medical devices such as syringes, needles, needlesafety and injection systems, infusion therapy and medication management solutions, as well as vascular access, urology and oncology devices acquired through its interventional business.